TTRX
Turn Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.74
+1.61%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +16.5%
- EPS
- -23.5%
Three-year CAGR
- Revenue
- —
- EBITDA
- -82.5%
- EBIT
- —
- Net income
- -80.6%
- EPS
- -76.9%
- Free cash flow
- -85.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026